In this teaser for Around the Practice, Omid Hamid, MD, of Cedars-Sinai The Angeles Clinic and Research Institute, introduces an upcoming multidisciplinary roundtable focused on cutaneous squamous cell carcinoma (cSCC).
Around the Practice: Epidemiology and Challenges in Advanced Cutaneous Squamous Cell Carcinoma
Experts unpack unresectable cutaneous squamous cell carcinoma, weighing PD-1/PD-L1 immunotherapy benefits and risks in older, comorbid patients.
Experts unpack advanced cutaneous squamous cell carcinoma risks, comorbidities, and PD-1/PD-L1 immunotherapy strategies for unresectable disease.
NP Schollenberger addresses how she interprets and communicates efficacy data to patients.
Dr. Hamid presents a 71-year-old male smoker with coronary artery disease and a 3.5 cm cervical CSCC lesion that has recurred after multiple surgical resections and adjuvant radiation therapy.
Dr. Zeitouni compares immune-mediated adverse event rates across checkpoint inhibitor agents in advanced CSCC.
Dr. Hamid presents an 86-year-old retired construction worker with diabetes, hypertension, and prior basal cell carcinoma, now with a 2.8 cm facial CSCC lesion and imaging-confirmed pulmonary metastases.
Both panelists describe multidisciplinary care coordination models.
NP Schollenberger addresses the particularly challenging and understudied population of immunocompromised patients with advanced CSCC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Study Redefines Functional High-Risk Multiple Myeloma in Modern-Therapy Era
2
Half a Year Into the Breast Biopsy Needle Shortage, Clinicians Lean on Networks, Not Workarounds
3
Managing Safety and Infection Risk With Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4
Key Clinical Takeaways in Newly Diagnosed Multiple Myeloma
5